9 Feb 2023 , 10:24 AM
Result date: 14th February, 2023
Recommendation: Buy
Target price: Rs 5,150
Apollo Hospitals Enterprise could post revenue growth of 20% over the year-ago quarter and 3% sequentially. Store addition and higher sales from existing stores could drive strong growth in pharmacy revenue.
EBITDA margin though could decline both over the year-ago quarter and sequentially during the quarter. Analysts at IIFL Securities expect Apollo’s growth momentum to sustain across all verticals, thereby leading to 17% EBITDA CAGR for the company over FY22-25.
Profit After Tax (PAT) could decline 2% over the year-ago quarter, but grow 10% sequentially.
Important management insights to watch out for:
December 2022 estimates |
YoY change |
QoQ change |
|
Revenue (Rs mn) |
43,817 |
20% |
3% |
EBITDA (Rs mn) |
5,674 |
(3)% |
0% |
EBITDA margin |
12.9% |
(318) bps |
(35) bps |
Profit After Tax (Rs mn) |
2,237 |
(2)% |
10% |
Source: IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.